Literature DB >> 19346236

Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks.

Xuewen Song1, Valeria Di Giovanni, Ning He, Kairong Wang, Alistair Ingram, Norman D Rosenblum, York Pei.   

Abstract

To elucidate the molecular pathways that modulate renal cyst growth in ADPKD, we performed global gene profiling on cysts of different size (<1 ml, n = 5; 10-20 ml, n = 5; >50 ml, n = 3) and minimally cystic tissue (MCT, n = 5) from five PKD1 human polycystic kidneys using Affymetrix HG-U133 Plus 2.0 arrays. We used gene set enrichment analysis to identify overrepresented signaling pathways and key transcription factors (TFs) between cysts and MCT. We found down-regulation of kidney epithelial restricted genes (e.g. nephron segment-specific markers and cilia-associated cystic genes such as HNF1B, PKHD1, IFT88 and CYS1) in the renal cysts. On the other hand, PKD1 cysts displayed a rich profile of gene sets associated with renal development, mitogen-mediated proliferation, cell cycle progression, epithelial-mesenchymal transition, hypoxia, aging and immune/inflammatory responses. Notably, our data suggest that up-regulation of Wnt/beta-catenin, pleiotropic growth factor/receptor tyrosine kinase (e.g. IGF/IGF1R, FGF/FGFR, EGF/EGFR, VEGF/VEGFR), G-protein-coupled receptor (e.g. PTGER2) signaling was associated with renal cystic growth. By integrating these pathways with a number of dysregulated networks of TFs (e.g. SRF, MYC, E2F1, CREB1, LEF1, TCF7, HNF1B/ HNF1A and HNF4A), our data suggest that epithelial dedifferentiation accompanied by aberrant activation and cross-talk of specific signaling pathways may be required for PKD1 cyst growth and disease progression. Pharmacological modulation of some of these signaling pathways may provide a potential therapeutic strategy for ADPKD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19346236     DOI: 10.1093/hmg/ddp165

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  113 in total

1.  Role of genetic modifiers in an orthologous rat model of ARPKD.

Authors:  Caitlin C O'Meara; Matthew Hoffman; William E Sweeney; Shirng-Wern Tsaih; Bing Xiao; Howard J Jacob; Ellis D Avner; Carol Moreno
Journal:  Physiol Genomics       Date:  2012-06-05       Impact factor: 3.107

2.  Epithelial Vasopressin Type-2 Receptors Regulate Myofibroblasts by a YAP-CCN2-Dependent Mechanism in Polycystic Kidney Disease.

Authors:  Nidhi Dwivedi; Shixin Tao; Abeda Jamadar; Sonali Sinha; Christianna Howard; Darren P Wallace; Timothy A Fields; Andrew Leask; James P Calvet; Reena Rao
Journal:  J Am Soc Nephrol       Date:  2020-06-17       Impact factor: 10.121

3.  Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD.

Authors:  Xia Zhou; Lucy X Fan; Dorien J M Peters; Marie Trudel; James E Bradner; Xiaogang Li
Journal:  Hum Mol Genet       Date:  2015-04-15       Impact factor: 6.150

Review 4.  Role of chemokines, innate and adaptive immunity.

Authors:  Kurt A Zimmerman; Katharina Hopp; Michal Mrug
Journal:  Cell Signal       Date:  2020-04-20       Impact factor: 4.315

Review 5.  Complement activation in progressive renal disease.

Authors:  Amy Fearn; Neil Stephen Sheerin
Journal:  World J Nephrol       Date:  2015-02-06

Review 6.  Epigenetics and autosomal dominant polycystic kidney disease.

Authors:  Xiaogang Li
Journal:  Biochim Biophys Acta       Date:  2010-10-20

7.  Fundamental insights into autosomal dominant polycystic kidney disease from human-based cell models.

Authors:  Caroline Weydert; Jean-Paul Decuypere; Humbert De Smedt; Peter Janssens; Rudi Vennekens; Djalila Mekahli
Journal:  Pediatr Nephrol       Date:  2018-09-13       Impact factor: 3.714

8.  Biallelic Mutations in DNAJB11 are Associated with Prenatal Polycystic Kidney Disease in a Turkish Family.

Authors:  Esra Arslan Ateş; Ayberk Turkyilmaz; Kenan Delil; Ceren Alavanda; Mehmet Ali Söylemez; Bilgen Bilge Geçkinli; Pinar Ata; Ahmet Arman
Journal:  Mol Syndromol       Date:  2021-04-01

Review 9.  MicroRNAs in the pathogenesis of cystic kidney disease.

Authors:  Yu Leng Phua; Jacqueline Ho
Journal:  Curr Opin Pediatr       Date:  2015-04       Impact factor: 2.856

10.  PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice.

Authors:  Ronak Lakhia; Matanel Yheskel; Andrea Flaten; Ezekiel B Quittner-Strom; William L Holland; Vishal Patel
Journal:  Am J Physiol Renal Physiol       Date:  2017-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.